At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 16:00 ET
Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.
- Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
- Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
- R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
- Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access